The document provides an overview of changes to CPT codes for 2023, with a focus on changes relevant to clinical documentation. Key points include:
- 111 codes were added, 67 deleted, and 89 revised across various sections.
- The radiology section saw the addition of 1 code, and revisions to 5 codes related to ultrasound and nuclear medicine procedures.
- The laboratory/pathology section saw the addition of several new genomic sequencing procedure codes, as well as codes for new chemistry and microbiology tests.
- Definitions for genomic sequencing procedures were updated.
- Proprietary laboratory analysis codes saw the addition of several new tests related to oncology, neurology, and prostate cancer.
Comprehensive Medical Coding and Billing Training for the AAPC CPC Exam. Online Training with videos and Skype sessions. HIPAA Training included along with Medical Billing. Trainer is Dr Guptha, world record holder.
Comprehensive Medical Coding and Billing Training for the AAPC CPC Exam. Online Training with videos and Skype sessions. HIPAA Training included along with Medical Billing. Trainer is Dr Guptha, world record holder.
ICD-10 Presentation Takes Coding to New HeightsPYA, P.C.
PYA Staff Consultant Kim-Marie Walker updated physicians at Robins Air Force Base on the latest in ICD-10 as part of “Soaring Together: A Collaboration in Continuing Medical Education."
Comprehensive Medical Coding and Billing Training for the AAPC CPC Exam. Online Training with videos and Skype sessions. HIPAA Training included along with Medical Billing. Trainer is Dr Guptha, world record holder.
ICD-10-CM is the United States’ clinical modification of the World Health Organization’s (WHO) International Classification of Diseases (ICD) Tenth Revision. It is used to classify diseases and causes of illness recorded on health records, claims, and other vital information.
The U.S. Department of Health and Human Services (HHS) will require covered entities (i.e., health plans, health care providers, and health care clearinghouses) that conduct electronic HIPAA standard transactions to move from ICD-9 to the next generation ICD-10 code sets by October 1, 2015.
Medical coding is the process of transforming transcribed data into set of numerical codes using a system of numbers to represent various medical problems, (diagnoses), and treatments (procedures
Clinical Documentation Guidelines for ICD-10-CMPamela Marasco
How Do You Rate Yourself as an Adopter of Change? Assess your willingness to implement new clinical documentation standards for ICD-10-CM. Improve your practice for clinical documentation to ensure proper selection of ICD-10-CM Coding Guidelines. Because EVERYTHING IS CHANGING!
Clinical data management (CDM) is a covered part in the clinical trial and most commonly used tools for the purpose of effectivity of clinical research
Here you will learn how to identify the right code for your diagnosis by applying different strategies that help reduce the probability of coding error and save time.
This webinar will provide an in-depth review of the CPT/HCPCS code set changes that will be effective on July 1, 2023. The review will include additions and deletions to the CPT/HCPCS code set, revisions of code descriptors, payment changes, and rationale behind the changes.
ICD-10 Presentation Takes Coding to New HeightsPYA, P.C.
PYA Staff Consultant Kim-Marie Walker updated physicians at Robins Air Force Base on the latest in ICD-10 as part of “Soaring Together: A Collaboration in Continuing Medical Education."
Comprehensive Medical Coding and Billing Training for the AAPC CPC Exam. Online Training with videos and Skype sessions. HIPAA Training included along with Medical Billing. Trainer is Dr Guptha, world record holder.
ICD-10-CM is the United States’ clinical modification of the World Health Organization’s (WHO) International Classification of Diseases (ICD) Tenth Revision. It is used to classify diseases and causes of illness recorded on health records, claims, and other vital information.
The U.S. Department of Health and Human Services (HHS) will require covered entities (i.e., health plans, health care providers, and health care clearinghouses) that conduct electronic HIPAA standard transactions to move from ICD-9 to the next generation ICD-10 code sets by October 1, 2015.
Medical coding is the process of transforming transcribed data into set of numerical codes using a system of numbers to represent various medical problems, (diagnoses), and treatments (procedures
Clinical Documentation Guidelines for ICD-10-CMPamela Marasco
How Do You Rate Yourself as an Adopter of Change? Assess your willingness to implement new clinical documentation standards for ICD-10-CM. Improve your practice for clinical documentation to ensure proper selection of ICD-10-CM Coding Guidelines. Because EVERYTHING IS CHANGING!
Clinical data management (CDM) is a covered part in the clinical trial and most commonly used tools for the purpose of effectivity of clinical research
Here you will learn how to identify the right code for your diagnosis by applying different strategies that help reduce the probability of coding error and save time.
This webinar will provide an in-depth review of the CPT/HCPCS code set changes that will be effective on July 1, 2023. The review will include additions and deletions to the CPT/HCPCS code set, revisions of code descriptors, payment changes, and rationale behind the changes.
2024 CPT® Code Updates (CDM Focused) - Part 1Health Catalyst
Each year the CPT and the HCPCS code sets undergo significant changes, and your staff needs to be aware of the changes in order to ensure a smooth transition into 2024. Join us for a discussion of the new, deleted, and revised CPT codes and associated guidelines for 2024. This is part one in a three-part series, with a CDM focus.
During these complimentary webinars, we will empower you to correctly apply the new and revised codes and discuss the rationale behind this year’s changes. This presentation will be geared towards hospital staff with a focus on the non-surgical sections of the CPT book.
Conferència a càrrec d'Enriqueta Felip. Oncòloga de l'Hospital Vall d'Hebron de Barcelona. Líder en la investigació de càncer de pulmó al VHIO. Membre de la Junta Directiva de la Societat Espanyola d'Oncologia Mèdica i de l'European Society for Medical Oncology. En el marc de la Jornada "Els nous reptes de la Medicina de Precisió" organitzada el 12 de novembre per la Societat Catalana de Gestió Sanitària
Darby Kammeraad, a Field Application Scientist at Golden Helix, gives some insight into the advantages of VarSeq's capability with annotations. The number of annotation topics to cover is seemingly limitless. In this webcast, he focuses on key elements that demonstrate the value of Golden Helix's curated annotations available in VarSeq and address some important considerations from our users. We also cover the types and effective utilization of annotations in VarSeq. Finally, he covers how users can create their own annotation sources from the Convert Wizard tool.
Recent advances toward preclinical and clinical translation of photoacoustic ...hoormohameed2019
Photoacoustic imaging is an emerging hybrid imaging modality that can provide multicontrast,
multiscale imaging of biological features ranging from organelles to organs. The three major embodiments of
photoacoustic imaging are microscopy, endoscopy, and computed tomography. Photoacoustic tomography
(PAT) or photoacoustic computed tomography allows deep-tissue imaging, and hence it is more suitable for
whole body preclinical/clinical imaging applications
A quick introduction of Genomic Testing Cooperative (GTC).
We strive to offer advanced genomic testing to communities everywhere at an affordable price.
We utilize a cooperative business model that enables academic and commercial laboratories to help physicians treat patients locally with the most advanced precision medicine.
We embrace disruptive deep learning and advanced technology to create scalable efficiencies, incomparable precision, and a more personalized approach to patient care.
https://www.genomictestingcooperative.com
Chair and Presenters Taofeek K. Owonikoko, MD, PhD, Anne Chiang, MD, PhD, FASCO, and Jared Weiss, MD, prepared useful Practice Aids pertaining to small cell lung cancer for this CME/MOC/AAPA/IPCE activity titled “Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Accelerating the Transition of Emerging Strategies to the Clinic.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at https://bit.ly/426IDlG. CME/MOC/AAPA/IPCE credit will be available until March 23, 2025.
Calcitonin is a hormone that is produced in humans by the parafollicular cells (commonly known as C-cells) of the Thyroid Gland. Calcitonin is involved in helping to regulate levels of calcium and phosphate in the blood, opposing the action of Parathyroid Hormone. This means that it acts to reduce calcium levels in the blood. However, the importance of this role in humans is unclear, as patients who have very low or very high levels of calcitonin show no adverse effects.
From Bits to Bedside: Translating Big Data into Precision Medicine and Digita...Dexter Hadley
Lecture Objectives:
1) To use examples from my research to define and introduce the ideals of precision medicine and digital health. 2) To introduce how large scale population-wide analysis of data can be used to facilitate these two ideals. 3) To introduce how freely available open data can be used to facilitate these two ideals. 4) To show how mobile technology can be used to facilitate these two ideals.
Translational Genomics and Prostate Cancer: Meet the NGS Experts Series Part 2QIAGEN
Advanced prostate cancer is highly heterogeneous but this inter-patient heterogeneity has until recently not been understood. We have through an international research effort dissected the molecular landscape of advanced castration resistant prostate, elucidating key molecular targets in this group of diseases. We have also shown that PARP inhibitors have antitumor activity against a significant proportion of these cancers, mainly in men whose cancers harbor DNA repair defects.
Empowering ACOs: Leveraging Quality Management Tools for MIPS and BeyondHealth Catalyst
Join us as we delve into the crucial realm of quality reporting for MSSP (Medicare Shared Savings Program) Accountable Care Organizations (ACOs).
In this session, we will explore how a robust quality management solution can empower your organization to meet regulatory requirements and improve processes for MIPS reporting and internal quality programs. Learn how our MeasureAble application enables compliance and fosters continuous improvement.
Unlock the Secrets to Optimizing Ambulatory Operations Efficiency and Change ...Health Catalyst
Today’s healthcare leaders are seeking technology solutions to optimize efficiencies and improve patient care. However, without effective change management and strategies in place, healthcare leaders struggle to strategically improve patient flow, space, to strategically improve patient flow, space, and schedule management, and implement daily huddles. The role of technology in supporting operational efficiency and change management initiatives is inevitable.
During this webinar, attendees will learn how to optimize Ambulatory Operational Efficiencies and Change Management. Attendees will also learn about the importance of visual management boards in enhancing clinic performance and insights into effective change management approaches.
Patient expectations are rising, and organizations are continuously being asked to do more with less.
Additionally, the convergence of several significant emerging market and policy trends, economic uncertainty, labor force shortages, and the end of the COVID-19 public health emergency has created a unique set of challenges for healthcare organizations.
Attend this timely webinar to learn about new trends and their impact on key healthcare issues, such as patient engagement, migration to value-based care, analytics adoption, the use of alternative care sites, and data governance and management challenges.
During this webinar, we will discuss the complexities of AI, trends, and platforms in the industry. Dive deep into understanding the true essence of AI, exploring its potential, real-world use cases, and common misconceptions. Gain valuable insights into the latest technology trends impacting healthcare and discover strategies for maximizing ROI in your technology investments.
Explore the profound impact of data literacy on healthcare organizations and how it shapes the utilization of data and technology for transformative outcomes. Understand the top technology priorities for healthcare organizations and learn how to navigate the digital landscape effectively. Furthermore, simplify industry jargon by defining common data elements, fostering clearer communication and collaboration across stakeholders.
Finally, uncover the transformative potentials of platforms in healthcare and how they can revolutionize scalability, interoperability, and innovation within your organization. Don't miss this opportunity to gain invaluable insights from industry experts and stay ahead in the ever-evolving healthcare landscape. Reserve your spot now for an enlightening journey into the future of healthcare technology!
Three Keys to a Successful Margin: Charges, Costs, and LaborHealth Catalyst
How can cost management and complete charge capture protect and enhance the margin?
In this webinar, we will look at 2024 margin pressures likely to impact your organization’s financial resiliency. This presentation will also share how organizations can move from Fee-for-Service to Value; bringing Cost to the forefront.
2024 CPT® Updates (Professional Services Focused) - Part 3Health Catalyst
Each year the CPT code set undergoes significant changes. Physicians and their office staff need to be aware of the changes in order to ensure a smooth transition into 2024. Join us for a discussion of the new, deleted and revised CPT codes and associated guidelines for 2024. This presentation will focus on the changes to the CPT dataset and the associated work RVU value changes that impact professional service reporting.
During this complimentary webinar, we will empower you to correctly apply the new and revised codes and discuss the rationale behind this year’s changes. You will leave with an understanding of the financial implications of the changes on your practice.
2024 CPT® Code Updates (HIM Focused) - Part 2Health Catalyst
Each year the CPT code set and the HCPCS code set undergo significant changes, and your coding staff needs to be aware of the changes in order to ensure a smooth transition into 2024. Join us for a discussion of the new, deleted and revised CPT codes and associated guidelines for 2024. This is part two in a three-part series.
During these complimentary webinars, we will empower you to correctly apply the new and revised codes and discuss the rationale behind this year’s changes. This presentation will be geared towards hospital staff with a focus on the surgical section of the CPT book in addition to surgical Category III codes.
What’s Next for Hospital Price Transparency in 2024 and BeyondHealth Catalyst
The Centers for Medicare & Medicaid Services (CMS) published updates to the hospital price transparency requirements in the CY 2024 Outpatient Prospective Payment System (OPPS) Final Rule. The updates will be phased in over the next 14 months and include several significant changes including the use of a CMS-mandated template, a requirement for an affirmation statement from the hospital, and several new data elements. Join us to discover what changes are scheduled for implementation in 2024 and 2025 and how they’ll impact your facility.
During this complimentary 60-minute webinar, we’ll analyze the key provisions of the Price Transparency regulations and provide insights to help you prepare for the upcoming changes.
Automated Patient Reported Outcomes (PROs) for Hip & Knee ReplacementHealth Catalyst
What was once voluntary reporting will soon be made mandatory with penalties.
On July 1, 2024, all health systems will be required to collect Patient Reported Outcome Measures (PROM) as part of the Centers for Medicare & Medicaid Services (CMS) regulation for the following measures:
Hospital-Level, Risk Standardized Patient-Reported Outcomes Performance Measure (PRO-PM) Following Elective Primary Total Hip Arthroplasty (THA) and/or Total Knee Arthroplasty (TKA)
Hospital-Level Risk-Standardized Complication Rate (RSCR) Following Elective Primary THA/TKA
Are you equipped to handle these new requirements?
Mandatory data collection begins April 1, 2024, and failure to submit timely data can result in a 25 percent reduction in payments by Medicare.
Attend this webinar to learn how mobile engagement can empower your organization to meet this requirement.
2024 Medicare Physician Fee Schedule (MPFS) Final Rule UpdatesHealth Catalyst
According to the Centers for Medicare & Medicaid Services (CMS), the calendar year (CY) 2024 MPFS final rule was created to advance health equity and improve access to affordable healthcare. This webinar will cover the major policy updates of the MPFS final rule including updates to the telehealth services policy and remote monitoring services and enrollment of MFTs and MHCs as Medicare providers. The conversation will also cover policy changes on split (or shared) evaluation and management (E/M) visits, and the Appropriate Use Criteria (AUC) for Advanced Diagnostic Imaging.
What's Next for OPPS: A Look at the 2024 Final RuleHealth Catalyst
During this webinar, we’ll analyze the key provisions of the OPPS final rule and identify the significant changes for the coming year to help prepare your staff for compliance with the 2024 Medicare outpatient billing guidelines.
Insight into the 2024 ICD-10 PCS Updates - Part 2Health Catalyst
Prepare for mandatory ICD-10 PCS diagnosis code updates, which take effect on October 1, 2023. By attending this 60-minute educational session, medical coders and healthcare professionals will gain a comprehensive understanding of the changes to the 2024 ICD-10 procedure codes and their guidelines, enabling accurate and compliant coding for optimal billing and reimbursement.
Vitalware Insight Into the 2024 ICD10 CM Updates.pdfHealth Catalyst
Prepare for mandatory ICD-10 CM diagnosis code updates, which take effect on October 1, 2023. By attending this 60-minute educational session, medical coders and healthcare professionals will gain a comprehensive understanding of the changes to the 2024 ICD-10 diagnosis codes and their guidelines, along with major complication or comorbidity (MCC), complication or comorbidity (CC), and Medicare Severity Diagnosis Related Groups (MS-DRGs) classification changes. With this information, professionals can ensure accurate and compliant diagnosis coding for optimal billing and reimbursement.
Driving Value: Boosting Clinical Registry Value Using ARMUS SolutionsHealth Catalyst
Many hospitals today face a perfect storm of operational and financial challenges. With increasing competition from outpatient facilities and rising care costs negatively impacting budgets, now is the time to boost your clinical registry’s value. However, collecting and analyzing data can be time-consuming and costly without the right tools. During this webinar, we will share insights and best practices for increasing the value of registry participation and how it’s possible to reduce costs while improving outcomes using the ARMUS Product Suite.
Tech-Enabled Managed Services: Not Your Average OutsourcingHealth Catalyst
During this webinar you'll learn the following:
The importance of optimizing performance, reducing labor costs and sourcing talent given current market challenges.
Highlighting the need for a balanced approach to cost reduction.
How to reap the benefits of outsourcing (cost cutting, expertise, etc) while protecting yourself from the collateral damage that often comes with them.
How Managing Chronic Conditions Is Streamlined with Digital TechnologyHealth Catalyst
Chronic conditions across the United States are prevalent and continue to rise. Managing one or more chronic diseases can be very challenging for patients who may be overwhelmed or confused about their care plan and may not have access to the resources they need. At the same time, care teams are overburdened, making it difficult to provide the support these patients require to stay as healthy as possible. A new approach to chronic condition management leverages technology to enable organizations to scale high-quality care, identify gaps in care, provide personalized support, and monitor patients on an ongoing basis. Such streamlined management will result in better outcomes, reduced costs, and more satisfied patients.
COVID-19: After the Public Health Emergency EndsHealth Catalyst
In this fast-paced webinar, we will discuss the impact of the end of the public health emergency (PHE), including upcoming changes to the different flexibilities allowed during the PHE and the timeline for when these flexibilities will end. We’ll also cover coding changes and reimbursement updates.
Automated Medication Compliance Tools for the Provider and PatientHealth Catalyst
When it comes to sustaining patient health outcomes, compliance and adherence to medication regimens are critically important, especially as providers manage patients with complex care needs and multiple medications. But, with provider burnout and staffing shortages at an all-time high, an efficient solution is critical. The use of automated medication management workflows to decrease provider burnout, while improving both medication compliance and patient engagement, is the way forward.
A Facility-Focused Guide to Applying Modifiers Corectly.pptxHealth Catalyst
This webinar is a review of how to appropriately assign frequently misapplied CPT and HCPCS modifiers. Older modifiers and newly added modifiers, that were effective January 1, 2023, will be covered. This webinar is focused on modifiers that should be used on the facility side. While some of these modifiers can also be used on the professional side, this presentation does not focus on assigning modifiers on the professional side. For information regarding applying modifiers on the professional side, please see part one of this series--A Physician-Focused Guide to Applying Modifiers Correctly.
Self-Service Analytics: How to Use Healthcare Business IntelligenceHealth Catalyst
Self-service analytics can empower healthcare organizations to better leverage business intelligence, enabling non-expert users to explore data sets, create custom reports and dashboards, and share valuable insights. However, without the right foundation, self-service analytics won’t reach its potential. Four pillars for success include the following:
1. A data-centric culture.
2. Data literacy.
3. Leadership support.
4. A defined business goal.
Trauma Outpatient Center is a comprehensive facility dedicated to addressing mental health challenges and providing medication-assisted treatment. We offer a diverse range of services aimed at assisting individuals in overcoming addiction, mental health disorders, and related obstacles. Our team consists of seasoned professionals who are both experienced and compassionate, committed to delivering the highest standard of care to our clients. By utilizing evidence-based treatment methods, we strive to help our clients achieve their goals and lead healthier, more fulfilling lives.
Our mission is to provide a safe and supportive environment where our clients can receive the highest quality of care. We are dedicated to assisting our clients in reaching their objectives and improving their overall well-being. We prioritize our clients' needs and individualize treatment plans to ensure they receive tailored care. Our approach is rooted in evidence-based practices proven effective in treating addiction and mental health disorders.
Health Education on prevention of hypertensionRadhika kulvi
Hypertension is a chronic condition of concern due to its role in the causation of coronary heart diseases. Hypertension is a worldwide epidemic and important risk factor for coronary artery disease, stroke and renal diseases. Blood pressure is the force exerted by the blood against the walls of the blood vessels and is sufficient to maintain tissue perfusion during activity and rest. Hypertension is sustained elevation of BP. In adults, HTN exists when systolic blood pressure is equal to or greater than 140mmHg or diastolic BP is equal to or greater than 90mmHg. The
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdfSachin Sharma
This content provides an overview of preventive pediatrics. It defines preventive pediatrics as preventing disease and promoting children's physical, mental, and social well-being to achieve positive health. It discusses antenatal, postnatal, and social preventive pediatrics. It also covers various child health programs like immunization, breastfeeding, ICDS, and the roles of organizations like WHO, UNICEF, and nurses in preventive pediatrics.
For those battling kidney disease and exploring treatment options, understanding when to consider a kidney transplant is crucial. This guide aims to provide valuable insights into the circumstances under which a kidney transplant at the renowned Hiranandani Hospital may be the most appropriate course of action. By addressing the key indicators and factors involved, we hope to empower patients and their families to make informed decisions about their kidney care journey.
LGBTQ+ Adults: Unique Opportunities and Inclusive Approaches to CareVITASAuthor
This webinar helps clinicians understand the unique healthcare needs of the LGBTQ+ community, primarily in relation to end-of-life care. Topics include social and cultural background and challenges, healthcare disparities, advanced care planning, and strategies for reaching the community and improving quality of care.
ICH Guidelines for Pharmacovigilance.pdfNEHA GUPTA
The "ICH Guidelines for Pharmacovigilance" PDF provides a comprehensive overview of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines related to pharmacovigilance. These guidelines aim to ensure that drugs are safe and effective for patients by monitoring and assessing adverse effects, ensuring proper reporting systems, and improving risk management practices. The document is essential for professionals in the pharmaceutical industry, regulatory authorities, and healthcare providers, offering detailed procedures and standards for pharmacovigilance activities to enhance drug safety and protect public health.
4. Overview of 2023 Changes
CPT® Section Additions Deletions Revisions
Evaluation &
Management
1 26 50
Anesthesia 0 0 0
Surgery 33 19 22
Radiology 1 0 5
Pathology & Laboratory 11 0 3
PLA 9 0 0
Medicine 10 0 7
Category II 0 0 0
Category III 46 22 2
Totals 111 67 89
• Totals do not include codes added, deleted, or revised in CY 2021/2022 but appearing for the first time in the CY 2023 book
• Revised totals do not include codes with changes to short or medium descriptions only
6. Added Code - Radiology Section
76883 - Ultrasound, nerve(s) and accompanying structures throughout their
entire anatomic course in one extremity, comprehensive, including real-time
cine imaging with image documentation, per extremity
Requires evaluation of the entire course of a nerve in the extremity
Cannot be reported with 76882 for the same nerve
Comprehensive evaluation requires acquisition and permanent record of cine
clips and static images to demonstrate the anatomy
7. Revised Codes - Radiology Section
Code 2023 Long Description 2022 Long Description
76882 Ultrasound, limited, joint or focal evaluation of
other nonvascular extremity structure(s) (eg, joint
space, peri-articular tendon[s], muscle[s], nerve[s],
other soft-tissue structure[s], or soft-tissue
mass[es]), real-time with image documentation
Ultrasound, limited, joint or other nonvascular
extremity structure(s) (eg, joint space, peri-
articular tendon[s], muscle[s], nerve[s], other soft-
tissue structure[s], or soft-tissue mass[es]), real-
time with image documentation
76882 represents a limited evaluation of a joint or focal evaluation of a structure(s) in the extremity
other than a joint; evaluation will not include all of the required elements outlined in code 76881
Must have permanent records of imaging
8. Revised Codes - Radiology Section
Code 2023 Long Description 2022 Long Description
78803 Radiopharmaceutical localization of tumor,
inflammatory process or distribution of
radiopharmaceutical agent(s) (includes vascular flow
and blood pool imaging, when performed);
tomographic (SPECT), single area (eg, head, neck,
chest, pelvis), or acquisition, single day imaging
Radiopharmaceutical localization of tumor,
inflammatory process or distribution of
radiopharmaceutical agent(s) (includes vascular flow
and blood pool imaging, when performed);
tomographic (SPECT), single area (eg, head, neck,
chest, pelvis), single day imaging
78830 Radiopharmaceutical localization of tumor,
inflammatory process or distribution of
radiopharmaceutical agent(s) (includes vascular flow
and blood pool imaging, when performed);
tomographic (SPECT) with concurrently acquired
computed tomography (CT) transmission scan for
anatomical review, localization and
determination/detection of pathology, single area (eg,
head, neck, chest, pelvis), or acquisition, single day
imaging
Radiopharmaceutical localization of tumor,
inflammatory process or distribution of
radiopharmaceutical agent(s) (includes vascular flow
and blood pool imaging, when performed);
tomographic (SPECT) with concurrently acquired
computed tomography (CT) transmission scan for
anatomical review, localization and
determination/detection of pathology, single area (eg,
head, neck, chest, pelvis), single day imaging
9. Revised Codes - Radiology Section
Code 2023 Long Description 2022 Long Description
78831 Radiopharmaceutical localization of tumor, inflammatory process
or distribution of radiopharmaceutical agent(s) (includes vascular
flow and blood pool imaging, when performed); tomographic
(SPECT), minimum 2 areas (eg, pelvis and knees, chest and
abdomen) or separate acquisitions (eg, lung ventilation and
perfusion), single day imaging, or single area or acquisition over
2 or more days
Radiopharmaceutical localization of tumor, inflammatory
process or distribution of radiopharmaceutical agent(s)
(includes vascular flow and blood pool imaging, when
performed); tomographic (SPECT), minimum 2 areas (eg,
pelvis and knees, abdomen and pelvis), single day imaging,
or single area imaging over 2 or more days
78832 Radiopharmaceutical localization of tumor, inflammatory process
or distribution of radiopharmaceutical agent(s) (includes vascular
flow and blood pool imaging, when performed); tomographic
(SPECT) with concurrently acquired computed tomography (CT)
transmission scan for anatomical review, localization and
determination/detection of pathology, minimum 2 areas (eg,
pelvis and knees, chest and abdomen) or separate acquisitions
(eg, lung ventilation and perfusion), single day imaging, or single
area or acquisition over 2 or more days
Radiopharmaceutical localization of tumor, inflammatory
process or distribution of radiopharmaceutical agent(s)
(includes vascular flow and blood pool imaging, when
performed); tomographic (SPECT) with concurrently
acquired computed tomography (CT) transmission scan for
anatomical review, localization and determination/detection
of pathology, minimum 2 areas (eg, pelvis and knees,
abdomen and pelvis), single day imaging, or single area
imaging over 2 or more days
Codes revised to clarify differentiation between single area/acquisition exams versus 2+ acquisitions
with 2 different radiopharmaceuticals
11. Updated Definitions/Guidelines –
Genomic Sequencing Procedures (GSPs)
GSPs (81410-81471) are DNA or RNA sequence analysis methods that simultaneously
assay multiple genes or genetic regions relevant to a clinical situation.
They typically use next generation sequencing (NGS) or massively parallel sequencing
(MPS), but other technology may be used
May target specific combinations of genes or genetic material or assay the exome or
genome
The exome and genome procedures are designed to evaluate the genetic material in
totality or near totality
Codes are used when the components of the descriptor are performed regardless of
technique used
When a GSP assay includes genes listed in more than one code descriptor, select the
code for the primary disorder sought
When all components of the descriptor are not performed, use Tier 1-2 codes or 81479
12. Added Codes – Genomic Sequencing
Procedures (GSPs)
81418 – Drug metabolism (eg, pharmacogenomics) genomic sequence
analysis panel, must include testing of at least 6 genes, including CYP2C19,
CYP2D6, and CYP2D6 duplication/deletion analysis
81441 - Inherited bone marrow failure syndromes (IBMFS) (eg, Fanconi
anemia, dyskeratosis congenita, Diamond-Blackfan anemia, Shwachman-
Diamond syndrome, GATA2 deficiency syndrome, congenital
amegakaryocytic thrombocytopenia) sequence analysis panel, must include
sequencing of at least 30 genes, including BRCA2, BRIP1, DKC1, FANCA,
FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL,
GATA1, GATA2, MPL, NHP2, NOP10, PALB2, RAD51C, RPL11, RPL35A,
RPL5, RPS10, RPS19, RPS24, RPS26, RPS7, SBDS, TERT, and TINF2
13. Added Codes – Genomic Sequencing
Procedures (GSPs)
81449 – Targeted genomic sequence analysis panel, solid organ neoplasm,
5-50 genes (eg, ALK, BRAF, CDKN2A, EGFR, ERBB2, KIT, KRAS, MET,
NRAS, PDGFRA, PDGFRB, PGR, PIK3CA, PTEN, RET), interrogation for
sequence variants and copy number variants or rearrangements, if
performed; RNA analysis
81451 - Targeted genomic sequence analysis panel, hematolymphoid
neoplasm or disorder, 5-50 genes (eg, BRAF, CEBPA, DNMT3A, EZH2,
FLT3, IDH1, IDH2, JAK2, KIT, KRAS, MLL, NOTCH1, NPM1, NRAS),
interrogation for sequence variants, and copy number variants or
rearrangements, or isoform expression or mRNA expression levels, if
performed; RNA analysis
14. Added Codes – Genomic Sequencing
Procedures
81456 - Targeted genomic sequence analysis panel, solid organ or
hematolymphoid neoplasm or disorder, 51 or greater genes (eg, ALK, BRAF,
CDKN2A, CEBPA, DNMT3A, EGFR, ERBB2, EZH2, FLT3, IDH1, IDH2,
JAK2, KIT, KRAS, MET, MLL, NOTCH1, NPM1, NRAS, PDGFRA, PDGFRB,
PGR, PIK3CA, PTEN, RET), interrogation for sequence variants and copy
number variants or rearrangements, or isoform expression or mRNA
expression levels, if performed; RNA analysis
15. Revised Codes - GSP
Code 2023 Long Description 2022 Long Description
81445 Targeted genomic sequence analysis panel, solid organ neoplasm, 5-50
genes (eg, ALK, BRAF, CDKN2A, EGFR, ERBB2, KIT, KRAS, MET,
NRAS, PDGFRA, PDGFRB, PGR, PIK3CA, PTEN, RET), interrogation
for sequence variants and copy number variants or rearrangements, if
performed; DNA analysis or combined DNA and RNA analysis
Targeted genomic sequence analysis panel, solid organ neoplasm,
DNA analysis, and RNA analysis when performed, 5-50 genes (eg,
ALK, BRAF, CDKN2A, EGFR, ERBB2, KIT, KRAS, NRAS, MET,
PDGFRA, PDGFRB, PGR, PIK3CA, PTEN, RET), interrogation for
sequence variants and copy number variants or rearrangements, if
performed
81450 Targeted genomic sequence analysis panel, hematolymphoid neoplasm
or disorder, 5-50 genes (eg, BRAF, CEBPA, DNMT3A, EZH2, FLT3,
IDH1, IDH2, JAK2, KIT, KRAS, MLL, NOTCH1, NPM1, NRAS),
interrogation for sequence variants, and copy number variants or
rearrangements, or isoform expression or mRNA expression levels, if
performed; DNA analysis or combined DNA and RNA analysis
Targeted genomic sequence analysis panel, hematolymphoid
neoplasm or disorder, DNA analysis, and RNA analysis when
performed, 5-50 genes (eg, BRAF, CEBPA, DNMT3A, EZH2, FLT3,
IDH1, IDH2, JAK2, KRAS, KIT, MLL, NRAS, NPM1, NOTCH1),
interrogation for sequence variants, and copy number variants or
rearrangements, or isoform expression or mRNA expression levels, if
performed
81455 Targeted genomic sequence analysis panel, solid organ or
hematolymphoid neoplasm or disorder, 51 or greater genes (eg, ALK,
BRAF, CDKN2A, CEBPA, DNMT3A, EGFR, ERBB2, EZH2, FLT3, IDH1,
IDH2, JAK2, KIT, KRAS, MET, MLL, NOTCH1, NPM1, NRAS, PDGFRA,
PDGFRB, PGR, PIK3CA, PTEN, RET), interrogation for sequence
variants and copy number variants or rearrangements, or isoform
expression or mRNA expression levels, if performed; DNA analysis or
combined DNA and RNA analysis
Targeted genomic sequence analysis panel, solid organ or
hematolymphoid neoplasm, DNA analysis, and RNA analysis when
performed, 51 or greater genes (eg, ALK, BRAF, CDKN2A, CEBPA,
DNMT3A, EGFR, ERBB2, EZH2, FLT3, IDH1, IDH2, JAK2, KIT,
KRAS, MLL, NPM1, NRAS, MET, NOTCH1, PDGFRA, PDGFRB,
PGR, PIK3CA, PTEN, RET), interrogation for sequence variants and
copy number variants or rearrangements, if performed
16. Updated Definitions/Guidelines –
Genomic Sequencing Procedures (GSP)
Testing for somatic alterations in neoplasms may be reported differently based
on whether combined methods and analyses are used for both DNA and RNA
analytes, or if separate methods and analyses are used for each analyte
For targeted genomic sequence DNA analysis or for DNA and RNA analysis
using a single combined method, report 81445, 81450, or 81455
For targeted genomic sequence RNA analysis using a separate method, report
81449, 81451, or 81456
For targeted genomic sequence DNA analysis and RNA analysis performed
separately, report 81445, 81450, or 81455 for the DNA analysis AND 81449,
81451, or 81456 for the RNA analysis
17. Added Code – Chemistry
84433 – Thiopurine S-methyltransferase (TPMT)
Used to detect a thiopurine methyltransferase (TPMT) deficiency and to
determine the risk of developing severe side effects if treated with the class
of immune-suppressing thiopurine drugs that includes azathioprine,
mercaptopurine, and thioguanine
18. Added Codes – Microbiology
87467 - Hepatitis B surface antigen (HBsAg), quantitative
Primarily used to monitor drug therapy; for qualitative analysis, see 87340
87468 - Infectious agent detection by nucleic acid (DNA or RNA); Anaplasma
phagocytophilum, amplified probe technique
87469 - Infectious agent detection by nucleic acid (DNA or RNA); Babesia
microti, amplified probe technique
87478 - Infectious agent detection by nucleic acid (DNA or RNA); Borrelia
miyamotoi, amplified probe technique
87484 - Infectious agent detection by nucleic acid (DNA or RNA); Ehrlichia
chaffeensis, amplified probe technique
New codes will allow for greater specificity in tracking of tick-borne illnesses
20. Added Codes – PLA
0355U - APOL1 (apolipoprotein L1) (eg, chronic kidney disease), risk variants
(G1, G2)
Apolipoprotein L1 (APOL1) Renal Risk Variant Genotyping from Quest Diagnostics®
Used to assist in evaluation of a potential kidney transplant donor
0356U - Oncology (oropharyngeal), evaluation of 17 DNA biomarkers using
droplet digital PCR (ddPCR), cell-free DNA, algorithm reported as a
prognostic risk score for cancer recurrence
NavDx® from Naveris, Inc.
Circulating DNA blood test that aids in the detection of HPV-driven cancer
21. Added Codes – PLA
0357U - Oncology (melanoma), artificial intelligence (AI)-enabled quantitative
mass spectrometry analysis of 142 unique pairs of glycopeptide and product
fragments, plasma, prognostic, and predictive algorithm reported as likely,
unlikely, or uncertain benefit from immunotherapy agents
DAWN™ IO Melanoma from InterVenn Biosciences
Measures glycoproteins using AI technology to match cancer patients with best therapy
0358U - Neurology (mild cognitive impairment), analysis of β-amyloid 1-42
and 1-40, chemiluminescence enzyme immunoassay, cerebral spinal fluid,
reported as positive, likely positive, or negative
Lumipulse® G β-Amyoid Ratio (1-42/1-40) Test by Fujirebio Diagnostics, Inc
Measures β-Amyloid to detect formation of amyloid plaques early in Alzheimer’s disease
22. Added Codes – PLA
0359U - Oncology (prostate cancer), analysis of all prostate-specific antigen
(PSA) structural isoforms by phase separation and immunoassay, plasma,
algorithm reports risk of cancer
IsoPSA® from Cleveland Diagnostics, Inc
PSA assay for patients with a PSA > 4ng/mL to help with decision for biopsy procedure
0360U - Oncology (lung), enzyme-linked immunosorbent assay (ELISA) of 7
autoantibodies (p53, NY-ESO-1, CAGE, GBU4-5, SOX2, MAGE A4, and
HuD), plasma, algorithm reported as a categorical result for risk of
malignancy
Nodify CDT® from Biodesix, Inc
Blood test to assess risk of lung cancer in patients with lung nodule(s)
23. Added Codes – PLA
0361U - Neurofilament light chain, digital immunoassay, plasma, quantitative
Neurofilament Light Chain (NfL) from Mayo Clinic
Blood biomarker test used to determine if cognitive issues may be related to a
neurodegenerative condition
0362U - Oncology (papillary thyroid cancer), gene-expression profiling via
targeted hybrid capture–enrichment RNA sequencing of 82 content genes
and 10 housekeeping genes, formalin-fixed paraffin embedded (FFPE)
tissue, algorithm reported as one of three molecular subtypes
Thyroid GuidePx® from Protean BioDiagnostics
NGS RNA sequencing of 82 genes to determine molecular subtype of papillary thyroid
cancer
24. Added Codes – PLA
0363U - Oncology (urothelial), mRNA, gene-expression profiling by real-time
quantitative PCR of 5 genes (MDK, HOXA13, CDC2 [CDK1], IGFBP5, and
CXCR2), utilizing urine, algorithm incorporates age, sex, smoking history, and
macrohematuria frequency, reported as a risk score for having urothelial
carcinoma
Cxbladder™ Triage from Pacific Edge Diagnostics USA, Ltd
Measures gene expression levels of five biomarkers using urine to determine risk of
bladder cancer
26. Added Code – Vaccines/Toxoids
90678 - Respiratory syncytial virus vaccine, preF, subunit, bivalent, for
intramuscular use
RSVpreF vaccine (will be active when approved by the FDA)
Indicated for patients 60 years and older and for patients in their 2nd or 3rd trimester of
pregnancy
27. Added Codes – Ophthalmology Services
92066 - Orthoptic training; under supervision of a physician or other qualified
health care professional
Change made to differentiate whether physician or technician are performing the
procedure
28. Revised Code – Ophthalmology Services
Code 2023 Long Description 2022 Long Description
92065 Orthoptic training; performed by a physician or other
qualified health care professional
Orthoptic training
92229 Imaging of retina for detection or monitoring of disease;
point-of-care autonomous analysis and report, unilateral
or bilateral
Imaging of retina for detection or monitoring of
disease; point-of-care automated analysis and
report, unilateral or bilateral
92284 Diagnostic dark adaptation examination with
interpretation and report
Dark adaptation examination with interpretation and
report
29. Added Codes – Nerve Conduction Tests
95919 - Quantitative pupillometry with physician or other qualified health care
professional interpretation and report, unilateral or bilateral
Used in both immediate evaluation and ongoing management of traumatic brain injuries
Provides objective data as opposed to subjective data
30. Added Codes – Behavior Management
Services
96202 - Multiple-family group behavior management/modification training for
parent(s)/guardian(s)/caregiver(s) of patients with a mental or physical health
diagnosis, administered by physician or other qualified health care professional
(without the patient present), face-to-face with multiple sets of
parent(s)/guardian(s)/caregiver(s); initial 60 minutes
96203 - Multiple-family group behavior management/modification training for
parent(s)/guardian(s)/caregiver(s) of patients with a mental or physical health
diagnosis, administered by physician or other qualified health care professional
(without the patient present), face-to-face with multiple sets of
parent(s)/guardian(s)/caregiver(s); each additional 15 minutes (List separately in
addition to code for primary service)
Used to report face-to-face time spent providing group-based behavioral management or
modification training to parents, guardians, or caregivers
Behavior modification is the process of altering behavior patterns over a long-term period
using motivational techniques to replace unwanted behaviors with more positive behaviors
31. Added Codes – Cardiovascular
93569 - Injection procedure during cardiac catheterization including imaging
supervision, interpretation, and report; for selective pulmonary arterial angiography,
unilateral (List separately in addition to code for primary procedure)
93573 - Injection procedure during cardiac catheterization including imaging
supervision, interpretation, and report; for selective pulmonary arterial angiography,
bilateral (List separately in addition to code for primary procedure)
93574 - Injection procedure during cardiac catheterization including imaging
supervision, interpretation, and report; for selective pulmonary venous angiography of
each distinct pulmonary vein during cardiac catheterization (List separately in
addition to code for primary procedure)
93575 - Injection procedure during cardiac catheterization including imaging
supervision, interpretation, and report; for selective pulmonary angiography of major
aortopulmonary collateral arteries (MAPCAs) arising off the aorta or its systemic
branches, during cardiac catheterization for congenital heart defects, each distinct
vessel (List separately in addition to code for primary procedure)
32. Added Codes - Cardiovascular
Three new codes have been added to differentiate between angiography
of the pulmonary arteries (unilateral versus bilateral) and pulmonary
veins during cardiac catheterization (93569, 93573, 93574)
One new code has been added to capture angiography of major
aortopulmonary collateral arteries during cardiac catheterization (93575)
All codes include selective introduction and positioning of catheter, injection,
and all radiologic S&I
A distinct vessel must be selectively cannulated in order to report each
instance of 93574 or 93575
Superior or inferior pulmonary veins (93574) or named major aortopulmonary
collateral artery (MAPCA) (93575)
33. Image published in RSNA Journal, Vol.4, No.1, published online Feb 3, 2022, at
https://doi.org/10.1148/ryct.210157
34. Revised Code – Medicine/Cardiovascular
Code 2023 Long Description 2022 Long Description
93568 Injection procedure during cardiac
catheterization including imaging supervision,
interpretation, and report; for nonselective
pulmonary arterial angiography (List separately
in addition to code for primary procedure)
Injection procedure during cardiac
catheterization including imaging supervision,
interpretation, and report; for pulmonary
angiography (List separately in addition to code
for primary procedure)
93568 has been revised to report non-selective pulmonary arterial angiography
35. Updated Definitions & Guidelines –
Coronary Therapeutic Services
Percutaneous coronary intervention codes 92920-92944 are built on hierarchies
with more intensive services inclusive of lesser intensive services
All codes include angioplasty, when performed
Codes all include accessing and selectively catheterizing the vessel, crossing
the lesion, radiological S&I related to the procedure, closing the arteriotomy, and
performing imaging to verify outcome of the procedure
Diagnostic coronary angiography may be separately reported IF A) There is no prior
study available, and a full diagnostic study is performed; or B) A prior study is
available, but there is documentation that the prior study is inadequate, there has
been a clinical change in the patient since the prior study; or C) There is a clinical
change during the procedure that warrants a separate study
Percutaneous transluminal coronary lithotripsy may be separately reported using
0715T
36. Updated Definitions & Guidelines –
Cardiac Catheterization
New guidance given on appropriate codes to use during cardiac catheterization
for congenital versus non-congenital heart disease
Left ventriculography is included in LHC for non-congenital heart disease, but is
separately reported when performed for congenital heart defects using 93565
Supravalvular aortography is separately reported using 93567
Pulmonary angiography and selective venous angiography are separately
reported using appropriate code(s)
Code 93463 is reported when drugs are given for the specific purpose of
evaluating hemodynamic response through repeat hemodynamic measurements
93463 is not reported for administration of drugs during percutaneous coronary
intervention; during assessment of coronary pressure, flow, or resistance; or during
imaging procedures
37. Updated Definitions & Guidelines –
Remote Therapeutic Monitoring
Used to report review and monitoring of data related to signs, symptoms, and
functions of a therapeutic response. Data may represent objective device-
generated data or subjective data from patient
Codes 98976-98978 are used to report services during a 30-day period; do not
report for monitoring of less than 16 days
Service must be ordered by a physician or other QHP, device must be a medical
device as defined by the FDA
Do not report with other physiologic monitoring services like glucose monitoring
or remote monitoring of physiologic parameters
98975 is reported once for each episode of care, defined as the beginning of
monitoring through the attainment of targeted treatment goal(s)
38. Added Code – Remote Therapeutic
Monitoring
One New Code Created to Report Remote Therapeutic Monitoring
Services
98978 – Remote therapeutic monitoring (eg, therapy adherence, therapy
response); device(s) supply with scheduled (eg, daily) recording(s) and/or
programmed alert(s) transmission to monitor cognitive behavioral therapy,
each 30 days
39. Revised Codes – Remote Therapeutic
Monitoring
Code 2023 Long Description 2022 Long Description
98975 Remote therapeutic monitoring (eg, therapy adherence,
therapy response); initial set-up and patient education on
use of equipment
Remote therapeutic monitoring (eg, respiratory system
status, musculoskeletal system status, therapy
adherence, therapy response); initial set-up and patient
education on use of equipment
98976 Remote therapeutic monitoring (eg, therapy adherence,
therapy response); device(s) supply with scheduled (eg,
daily) recording(s) and/or programmed alert(s)
transmission to monitor respiratory system, each 30 days
Remote therapeutic monitoring (eg, respiratory system
status, musculoskeletal system status, therapy
adherence, therapy response); device(s) supply with
scheduled (eg, daily) recording(s) and/or programmed
alert(s) transmission to monitor respiratory system, each
30 days
98977 Remote therapeutic monitoring (eg, therapy adherence,
therapy response); device(s) supply with scheduled (eg,
daily) recording(s) and/or programmed alert(s)
transmission to monitor musculoskeletal system, each 30
days
Remote therapeutic monitoring (eg, respiratory system
status, musculoskeletal system status, therapy
adherence, therapy response); device(s) supply with
scheduled (eg, daily) recording(s) and/or programmed
alert(s) transmission to monitor musculoskeletal system,
each 30 days
41. Added Codes - New & Emerging
Technology
Code Long Description
0738T Treatment planning for magnetic field induction ablation of malignant prostate tissue, using data from
previously performed magnetic resonance imaging (MRI) examination
0742T Absolute quantitation of myocardial blood flow (AQMBF), single-photon emission computed
tomography (SPECT), with exercise or pharmacologic stress, and at rest, when performed (List
separately in addition to code for primary procedure)
0738T may not be reported with 0739T (tissue ablation)
AQMBF done with PET imaging is reported using 78434
42. Added Codes - New & Emerging
Technology
Code Long Description
0740T Remote autonomous algorithm-based recommendation system for insulin dose calculation and
titration; initial set-up and patient education
0741T Remote autonomous algorithm-based recommendation system for insulin dose calculation and
titration; provision of software, data collection, transmission, and storage, each 30 days
New technology to provide patients with real-time information to calculate appropriate adjusted
insulin doses
Hygieia’s d-Nav® Technology
43. Added Codes
New & Emerging Technology
Code Long Description
0743T Bone strength and fracture risk using finite element analysis of functional data and bone mineral
density (BMD), with concurrent vertebral fracture assessment, utilizing data from a computed
tomography scan, retrieval and transmission of the scan data, measurement of bone strength and
BMD and classification of any vertebral fractures, with overall fracture-risk assessment,
interpretation and report
0743T includes vertebral fracture assessment, which differentiates this code from 0554T-0557T
0558T may be separately reported when performed with a concurrently obtained CT scan
44. Added Codes
New & Emerging Technology
Code Long Description
0749T Bone strength and fracture-risk assessment using digital X-ray radiogrammetry-bone mineral density
(DXR-BMD) analysis of bone mineral density (BMD) utilizing data from a digital X ray, retrieval and
transmission of digital X-ray data, assessment of bone strength and fracture risk and BMD,
interpretation and report
0750T Bone strength and fracture-risk assessment using digital X-ray radiogrammetry-bone mineral density
(DXR-BMD) analysis of bone mineral density (BMD) utilizing data from a digital X ray, retrieval and
transmission of digital X-ray data, assessment of bone strength and fracture risk and BMD,
interpretation and report; with single-view digital X-ray examination of the hand taken for the purpose
of DXR-BMD
0749T is reported when an appropriate digital x-ray is available
0750T is reported when a single digital x-ray of the hand is taken for DXR-BMD analysis; x-ray of
hand is not separately reported
45. Added Codes
New & Emerging Technology
Code Long Description
0751T Digitization of glass microscope slides for level II, surgical pathology, gross and microscopic
examination (List separately in addition to code for primary procedure)
0752T Digitization of glass microscope slides for level III, surgical pathology, gross and microscopic
examination (List separately in addition to code for primary procedure)
0753T Digitization of glass microscope slides for level IV, surgical pathology, gross and microscopic
examination (List separately in addition to code for primary procedure)
0754T Digitization of glass microscope slides for level V, surgical pathology, gross and microscopic
examination (List separately in addition to code for primary procedure)
0755T Digitization of glass microscope slides for level VI, surgical pathology, gross and microscopic
examination (List separately in addition to code for primary procedure)
Slides are scanned with images used for digital examination for pathologic diagnosis distinct from direct
visualization through a microscope
May not be used solely for education purposes, for developing a database for training or validation, or for
presentations
46. Added Codes
New & Emerging Technology
Code Long Description
0756T Digitization of glass microscope slides for special stain, including interpretation and report, group I,
for microorganisms (eg, acid fast, methenamine silver) (List separately in addition to code for
primary procedure)
0757T Digitization of glass microscope slides for special stain, including interpretation and report, group II,
for microorganisms (eg, acid fast, methenamine silver) (List separately in addition to code for
primary procedure)
0758T Digitization of glass microscope slides for special stain, including interpretation and report,
histochemical stain on frozen tissue block (List separately in addition to code for primary procedure)
0759T Digitization of glass microscope slides for special stain, including interpretation and report, group III,
for enzyme constituents (List separately in addition to code for primary procedure)
47. Added Codes
New & Emerging Technology
Code Long Description
0760T Digitization of glass microscope slides for immunohistochemistry or immunocytochemistry, per
specimen, initial single antibody stain procedure (List separately in addition to code for primary
procedure)
0761T Digitization of glass microscope slides for immunohistochemistry or immunocytochemistry, per
specimen, each additional single antibody stain procedure (List separately in addition to code for
primary procedure)
0762T Digitization of glass microscope slides for immunohistochemistry or immunocytochemistry, per
specimen, each multiplex antibody stain procedure (List separately in addition to code for primary
procedure)
0763T Digitization of glass microscope slides for morphometric analysis, tumor immunohistochemistry (eg,
Her-2/neu, estrogen receptor/progesterone receptor), quantitative or semiquantitative, per specimen,
each single antibody stain procedure, manual (List separately in addition to code for primary
procedure)
48. Added Codes
New & Emerging Technology
Code Long Description
0764T Assistive algorithmic electrocardiogram risk-based assessment for cardiac dysfunction (eg, low-
ejection fraction, pulmonary hypertension, hypertrophic cardiomyopathy); related to concurrently
performed electrocardiogram (List separately in addition to code for primary procedure)
0765T Assistive algorithmic electrocardiogram risk-based assessment for cardiac dysfunction (eg, low-
ejection fraction, pulmonary hypertension, hypertrophic cardiomyopathy); related to previously
performed electrocardiogram
0764T is an add-on code that may be reported with 93000 or 93010 once for each ECG tracing
performed
0765T may be reported only once for each previously performed ECG tracing
Anumana, Inc.
49. Added Codes
New & Emerging Technology
Code Long Description
0766T Transcutaneous magnetic stimulation by focused low-frequency electromagnetic pulse, peripheral
nerve, initial treatment, with identification and marking of the treatment location, including noninvasive
electroneurographic localization (nerve conduction localization), when performed; first nerve
0767T Transcutaneous magnetic stimulation by focused low-frequency electromagnetic pulse, peripheral
nerve, initial treatment, with identification and marking of the treatment location, including noninvasive
electroneurographic localization (nerve conduction localization), when performed; each additional nerve
(List separately in addition to code for primary procedure)
0768T Transcutaneous magnetic stimulation by focused low-frequency electromagnetic pulse, peripheral
nerve, subsequent treatment, including noninvasive electroneurographic localization (nerve conduction
localization), when performed; first nerve
0769T Transcutaneous magnetic stimulation by focused low-frequency electromagnetic pulse, peripheral
nerve, subsequent treatment, including noninvasive electroneurographic localization (nerve conduction
localization), when performed; each additional nerve (List separately in addition to code for primary
procedure)
50. Updated Definitions & Guidelines –
Transcutaneous Magnetic Nerve Stimulation
Codes 0766T-0769T describe transcutaneous magnetic stimulation, which is
performed to treat chronic nerve pain
The nerve is localized using magnetic stimulation, the skin is marked, and the
appropriate amplitude of stimulation is defined
Non-invasive nerve conduction may be used as guidance to confirm location and
may not be reported separately
A separate diagnostic nerve conduction study may be separately reported if
performed to determine need for treatment
51. Added Codes
New & Emerging Technology
Code Long Description
0770T Virtual reality technology to assist therapy (List separately in addition to code for primary procedure)
0771T Virtual reality (VR) procedural dissociation services provided by the same physician or other qualified
health care professional performing the diagnostic or therapeutic service that the VR procedural
dissociation supports, requiring the presence of an independent, trained observer to assist in the
monitoring of the patient's level of dissociation or consciousness and physiological status; initial 15
minutes of intraservice time, patient age 5 years or older
0772T Virtual reality (VR) procedural dissociation services provided by the same physician or other qualified
health care professional performing the diagnostic or therapeutic service that the VR procedural
dissociation supports, requiring the presence of an independent, trained observer to assist in the
monitoring of the patient's level of dissociation or consciousness and physiological status; each
additional 15 minutes intraservice time (List separately in addition to code for primary service)
0770T may be reported once per session during which VR technology is used
May be reported with 90832-90838, 90847-90853, 92507, 92507, 96158, 96159, 96164-96171,
97110, 97112, 97129, 97150, 97153=97155, 97158, 97530, 97533, 97535, 97537
52. Added Codes
New & Emerging Technology
Code Long Description
0773T Virtual reality (VR) procedural dissociation services provided by a physician or other qualified health
care professional other than the physician or other qualified health care professional performing the
diagnostic or therapeutic service that the VR procedural dissociation supports; initial 15 minutes of
intraservice time, patient age 5 years or older
0774T Virtual reality (VR) procedural dissociation services provided by a physician or other qualified health
care professional other than the physician or other qualified health care professional performing the
diagnostic or therapeutic service that the VR procedural dissociation supports; each additional 15
minutes intraservice time (List separately in addition to code for primary service)
VR procedural dissociation is a VR-based state of altered consciousness to decrease pain during a
procedure and increase procedural tolerance by establishing a computer-generated immersive
environment
0771T-0774T are not used to report administration of medications, moderate sedation, deep
sedation, or MAC
53. Added Codes
New & Emerging Technology
Code Long Description
0776T Therapeutic induction of intra-brain hypothermia, including placement of a mechanical temperature-
controlled cooling device to the neck over carotids and head, including monitoring (eg, vital signs
and sport concussion assessment tool 5 [SCAT5]), 30 minutes of treatment
0778T Surface mechanomyography (sMMG) with concurrent application of inertial measurement unit (IMU)
sensors for measurement of multi-joint range of motion, posture, gait, and muscle function
0779T Gastrointestinal myoelectrical activity study, stomach through colon, with interpretation and report
0783T Transcutaneous auricular neurostimulation, set-up, calibration, and patient education on use of
equipment
54. Deleted Codes
New & Emerging Technology
Deleted Code Suggested Replacement Codes
0470T – Optical coherence tomography (OCT) for microstructural and
morphological imaging of skin, image acquisition, interpretation, and
report; first lesion
96999
0471T - Optical coherence tomography (OCT) for microstructural and
morphological imaging of skin, image acquisition, interpretation, and
report; each additional lesion (List separately in addition to code for
primary procedure)
96999
55. Deleted Codes
New & Emerging Technology
Deleted Code Suggested Replacement Codes
0475T – Recording of fetal magnetic cardiac signal using at least 3
channels; patient recording and storage, data scanning with signal
extraction, technical analysis and result, as well as supervision, review,
and interpretation of report by a physician or other qualified health care
professional
93799
0476T - Recording of fetal magnetic cardiac signal using at least 3
channels; patient recording, data scanning, with raw electronic signal
transfer of data and storage
93799
0477T - Recording of fetal magnetic cardiac signal using at least 3
channels; signal extraction, technical analysis, and result
93799
0478T - Recording of fetal magnetic cardiac signal using at least 3
channels; review, interpretation, report by physician or other qualified
health care professional
93799
56. Deleted Codes
New & Emerging Technology
Deleted Code Suggested Replacement Codes
0487T – Biomechanical mapping, transvaginal, with report 58999
0493T - Contact near-infrared spectroscopy studies of lower extremity
wounds (eg, for oxyhemoglobin measurement)
93998
0497T - External patient-activated, physician- or other qualified health
care professional-prescribed, electrocardiographic rhythm derived event
recorder without 24-hour attended monitoring; in-office connection
93799
0498T - External patient-activated, physician- or other qualified health
care professional-prescribed, electrocardiographic rhythm derived event
recorder without 24-hour attended monitoring; review and interpretation
by a physician or other qualified health care professional per 30 days
with at least one patient-generated triggered event
93799
57. Deleted Codes
New & Emerging Technology
Deleted Code Suggested Replacement Codes
0514T – Intraoperative visual axis identification using patient fixation (List
separately in addition to code for primary procedure)
None
0702T - Remote therapeutic monitoring of a standardized online digital
cognitive behavioral therapy program ordered by a physician or other
qualified health care professional; supply and technical support, per 30
days
98978
0703T - Remote therapeutic monitoring of a standardized online digital
cognitive behavioral therapy program ordered by a physician or other
qualified health care professional; management services by physician or
other qualified health care professional, per calendar month
98978
58. Revised Codes – New & Emerging
Technology
CPT Code 2023 Long Description 2022 Long Description
0733T Remote real-time, motion capture–based
neurorehabilitative therapy ordered by a
physician or other qualified health care
professional; supply and technical support,
per 30 days
Remote body and limb kinematic measurement-
based therapy ordered by a physician or other
qualified health care professional; supply and
technical support, per 30 days
0734T Remote real-time, motion capture–based
neurorehabilitative therapy ordered by a
physician or other qualified health care
professional; treatment management
services by a physician or other qualified
health care professional, per calendar month
Remote body and limb kinematic measurement-
based therapy ordered by a physician or other
qualified health care professional; treatment
management services by a physician or other
qualified health care professional, per calendar
month
Editor's Notes
Code 76883 has been established to report ultrasound of nerve(s) and accompanying structures in a single extremity.
76881 – Ultrasound, complete joint
Prior to 2023, code 76882 described limited ultrasound of a joint or other nonvascular extremity structure and was intended to describe a focused ultrasound evaluation (ie, evaluation of a specific location on or around a specific structure, such as a cyst) of structures in the extremity such as a joint space or nerve.
Previously, these codes did not identify “acquisitions”–that is, separately obtained images with different radiopharmaceuticals, even if they were obtained on the same day and from the same anatomic site.
•Adding the term “acquisition” to the code descriptor sallows for more specific reporting (ie, according to anatomic area or acquisitions performed) and maintain uniformity in the code family.
•This allows better differentiation when reporting codes 78831 and 78832.The term “separate acquisition” was added to codes 78831 and 78832 to allow separate reporting when single area, same day images are performed for different reasons (eg, perfusion versus ventilation for the same lung).
* Concurrently acquired computed tomography (CT) transmission scans may be separately reported when performed with codes 78830 and 78832.
•For codes 78831 and 78832, the phrase “(eg, lung ventilation and perfusion)” was also added within each code descriptor along with the term “or acquisition.”
The complete genomic information within a sample or individual is known as the whole genome. Exons are the genome's protein-coding regions and are collectively known as the exome.
Tier I – 81105-81383
Tier II – 81400-81408 & 81479
81418 – Important that testing include at least 6 genes and must include listed genes
New codes created to report separate RNA analysis
81445-81455 were rephrased for clarity
Somatic mutation tests are broadly defined here as any test that measures changes in DNA, RNA, or chromosomes found in tumor tissue that is used to make cancer management decisions.
Affected individuals are at a high risk of experiencing bone marrow damage if they take thiopurine drugs. Many patients recover from the bone marrow damage once thiopurine drug use is stopped. When the bone marrow is damaged, infections can cause health problems.
Sci-B-Vac
Priority review was approved by FDA on 12/7/22
Orthoptic training is the treatment of defective visual habits, defects of binocular vision, and muscle imbalance (strabismus) by re-education of visual habits, exercise, and visual training.
92065 is now a parent code for 92066
92229 clarifies the true service performed since the service is considered autonomous (the machine interprets the data)
Quantitative pupillometry is the objective measurement of pupil size and reactivity through the use of an automatic, portable device that emits a standard light-emitting diode light source and records pupil reaction.
Counseling risk factor reduction and behavior change intervention codes (99401, 99402, 99403, 99404, 99406, 99407, 99408, 99409, 99411, 99412) are included and may not be separately reported on the same day as parent(s)/guardian(s)/caregiver(s) training services codes 96202, 96203 by the same provider.
Medical nutrition therapy (97802, 97803, 97804) provided to the identified patient may be reported on the same date of service as parent(s)/guardian(s)/caregiver(s) training service.
* Do not report for less than 31 minutes of therapy
Major aortopulmonary collateral arteries (MAPCAs) are congenital vessels that arise from the aorta or its first-order branches and are distally connected to the pulmonary arterial vasculature, thereby providing pulmonary blood flow.
While the morphologic right atrium and morphologic right ventricle are typically the right heart structures supplying blood flow to the pulmonary artery, in congenital heart disease the subpulmonic ventricle may be a morphologic left ventricle and the subpulmonic atrium may be a morphologic left atrium. For reporting purposes, when the morphologic left ventricle or left atrium is in a subpulmonic position due to congenital heart disease, catheter placement in either of these structures is considered part of right heart catheterization and does not constitute left heart catheterization.
Codes for congenital cardiac anomalies are not used for anomalous coronary arteries arising from the aorta or other coronary arteries, PFO, MVP, bicuspid aortic valve in the absence of other heart defects.
Cardiac catheterization services for anomalous coronary arteries arising from the aorta or off of other coronary arteries, patent foramen ovale, mitral valve prolapse, and bicuspid aortic valve, in the absence of other congenital heart defects, are reported with 93451-93464, 93566, 93567, 93568. However, when these conditions exist in conjunction with other congenital heart defects, 93593, 93594, 93595, 93596, 93597 may be reported. Evaluation of anomalous coronary arteries arising from the pulmonary arterial system is reported with the cardiac catheterization for congenital heart defects codes.
While the morphologic right atrium and morphologic right ventricle are typically the right heart structures supplying blood flow to the pulmonary artery, in congenital heart disease the subpulmonic ventricle may be a morphologic left ventricle and the subpulmonic atrium may be a morphologic left atrium. For reporting purposes, when the morphologic left ventricle or left atrium is in a subpulmonic position due to congenital heart disease, catheter placement in either of these structures is considered part of right heart catheterization and does not constitute left heart catheterization.
Remote therapeutic monitoring treatment management services are provided when a physician or other qualified health care professional uses the results of remote therapeutic monitoring to manage a patient under a specific treatment plan. To report remote therapeutic monitoring, the service must be ordered by a physician or other qualified health care professional. To report 98980, 98981, any device used must be a medical device as defined by the FDA. Do not use 98980, 98981 for time that can be reported using codes for more specific monitoring services.
0738T - The magnetic fluid was injected transperineally into the prostates according to a preplan. Patients received six thermal therapies of 60-min duration at weekly intervals using an alternating magnetic field applicator. 0738T is for treatment planning can’t be reported with 0739T
0742T - Absolute quantitation of myocardial blood flow (AQMBF) imaging is an additional physiological assessment during a pharmacologic stress/rest PET or PET/CT myocardial perfusion imaging. Following stress/rest PET or PET/CT myocardial perfusion imaging, images for PET myocardial perfusion imaging are acquired to allow quantitation of AQMBF. The report quantifies in ml/g/min for rest, stress, and indexed/reserve flow for each coronary bed and for the global left ventricular.
0558T —Computed tomography scan taken for the purpose of biomechanical computed tomography analysis, including vertebral fracture assessment, when performed
Sectra OneScreen® and dxr-online™ and estimates distal forearm bone mineral density (BMD) through a fully automated analysis of a standard projection digital X-ray image of the hand. To derive BMD, Sectra dxr-online and OneScreen applies the patented Digital X-ray Radiogrammetry (DXR) technique to the three middle metacarpal bones
0770T is typically used for skill-building in social communication, emotional regulation, and daily function
Can’t be used for patients under 5
Intraservice time is used to determine the appropriate code to report VR procedural dissociation and is defined as:◄
beginning with administration of the immersive VR technology, which at a minimum, includes audio, video, and proprioceptive feedback;
requiring continuous face-to-face attendance of the physician or other qualified health care professional. Once continuous face-to-face time with the patient has ended, additional face-to-face time with the patient is not added to the intraservice time;
ending when the procedure and the administration of the VR technology ends and the physician or other qualified health care professional is no longer continuously face-to-face with the patient;
0776T describes pro2cool® system to reduce cellular damage to brain following TBI
Code 0778T - The sensors are placed on the skin across the surface of a muscle in order to quantify muscle output, allowing clinicians to collect precise measurements about muscle performance and make data-driven decisions around clinical care, while providing important feedback to the individual patient FIGUR8
Code 0779T is intended to report GI myoelectrical activity study from the stomach through the colon.
•This study is a noninvasive procedure that assesses motility in the GI tract from the stomach through the colon. The study may be performed over several days. Typically, this assessment is performed for GI symptoms such as gastrointestinal pain, bloating, and distension.
Volume of 0514T was very low, which suggested that there was no need for the code.